About The ARANOTE Study
Randomized, double-blind, placebo-controlled multicenter phase III study (including 2 Canadian sites)
Adapted from NUBEQA® Product Monograph
- Median age: 70 years (range 43-93)
- Primary endpoint: radiographic Progression Free Survival (rPFS)
- Secondary endpoints include:
- Overall survival (OS), time to initiation of subsequent antineoplastic therapy, time to CRPC, time to pain progression
Primary Endpoint: Radiographic Progression-Free Survival
Adapted from NUBEQA® Product Monograph
- NUBEQA® + ADT significantly improved rPFSvs. placebo + ADT
- HR (95% CI):* 0.541 (0.413, 0.707), p<0.0001
- Number (%) of events was 128/446 (28.7%) for NUBEQA + ADT and 94/223 (42.2%) for placebo + ADT
32.5% of patients in the NUBEQA® + ADT arm and 42.5% of patients in the placebo + ADT arm received subsequent life-prolonging therapy.